Neurosciences Centre of Excellence, GlaxoSmithKline Medicines Research Centre, Verona, Italy.
Bioorg Med Chem Lett. 2010 Dec 15;20(24):7308-11. doi: 10.1016/j.bmcl.2010.10.067. Epub 2010 Oct 21.
A new class of selective NPS antagonist was developed starting from a commercially available product identified by screening activities. Experimental NMR observations and computational experiments allowed the discovery of a new class of derivatives. 5-Phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-one represents a new lead compound in the NPS antagonist field.
一种新型的选择性 NPS 拮抗剂是从通过筛选活动确定的市售产品开始开发的。实验 NMR 观察和计算实验允许发现一类新的衍生物。5-苯基-2-[2-(1-哌啶基羰基)苯基]-2,3-二氢-1H-吡咯并[1,2-c]咪唑-1-酮是 NPS 拮抗剂领域的一种新的先导化合物。